ES2084596T3 - Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas. - Google Patents

Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas.

Info

Publication number
ES2084596T3
ES2084596T3 ES89122964T ES89122964T ES2084596T3 ES 2084596 T3 ES2084596 T3 ES 2084596T3 ES 89122964 T ES89122964 T ES 89122964T ES 89122964 T ES89122964 T ES 89122964T ES 2084596 T3 ES2084596 T3 ES 2084596T3
Authority
ES
Spain
Prior art keywords
disease
felv
prototypes
isolated materials
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89122964T
Other languages
English (en)
Inventor
Edward A Hoover
James I Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Colorado State University Research Foundation
Original Assignee
Harvard University
Colorado State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University, Colorado State University Research Foundation filed Critical Harvard University
Application granted granted Critical
Publication of ES2084596T3 publication Critical patent/ES2084596T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/819—Viral vaccine for feline species, e.g. cats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CLONES MOLECULARES AISLADORES DEL VIRUS DE LEUCEMIA FELINA QUE CODIFICAN (A) UN VIRUS PROTOTIPO ALTAMENTE INFECCIOSO Y MINIMAMENTE PATOGENO, (B) UN GENOMA VARIANTE DE REPRODUCCION ANORMAL ASOCIADO A UNA INMUNODEFICIENCIA FATAL EN GATOS, SIMILAR AL SIDA (FAIDS O SIDA FELINO) O (C) UN GENOMA QUIMERICO DE REPRODUCCION NORMAL QUE INDUCE AL FAIDS. ESTOS CLONES MOLECULARES PUEDEN UTILIZARSE EN LA GENERACION DE LINEAS DE CELULAS QUE PRODUZCAN UN VIRUS INFECCIOSO UTIL EN LA PREPARACION DE VACUNAS O EN LA GENERACION DE VIREMIA O SISTEMAS QUE COMBATAN ENFERMEDADES.
ES89122964T 1988-12-13 1989-12-12 Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas. Expired - Lifetime ES2084596T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28413988A 1988-12-13 1988-12-13

Publications (1)

Publication Number Publication Date
ES2084596T3 true ES2084596T3 (es) 1996-05-16

Family

ID=23088994

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95100871T Expired - Lifetime ES2179854T3 (es) 1988-12-13 1989-12-12 Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas.
ES89122964T Expired - Lifetime ES2084596T3 (es) 1988-12-13 1989-12-12 Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES95100871T Expired - Lifetime ES2179854T3 (es) 1988-12-13 1989-12-12 Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas.

Country Status (12)

Country Link
US (1) US6042835A (es)
EP (2) EP0377842B1 (es)
JP (1) JP3164351B2 (es)
AT (2) ATE128730T1 (es)
AU (2) AU4616289A (es)
CA (1) CA2005311C (es)
DE (2) DE68924478T2 (es)
DK (1) DK172633B1 (es)
ES (2) ES2179854T3 (es)
GR (1) GR3018587T3 (es)
IE (1) IE74875B1 (es)
NZ (1) NZ231744A (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901778D0 (en) * 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
ZA93216B (en) * 1992-01-17 1993-08-18 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant.
GB9210337D0 (en) * 1992-05-14 1992-07-01 Univ Court Of The University O Feline leukaemia virus vaccine
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
ES2374526T3 (es) 2003-09-04 2012-02-17 Medarex, Inc. Vector de expresión.
AU2005229411B2 (en) * 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
US10988762B2 (en) 2017-02-16 2021-04-27 Bio-Rad Laboratories, Inc. Reverse transcriptases and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia
US4034081A (en) * 1973-09-18 1977-07-05 University Of Glasgow Vaccines against feline leukemia
GB1486186A (en) * 1973-09-18 1977-09-21 Univ Glasgow Vaccines against feline leukaemia and the group of diseases associated with feline leukaemis/virus infection
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
US4434157A (en) * 1979-12-18 1984-02-28 The Ohio State University Research Foundation Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
US4332793A (en) * 1979-12-18 1982-06-01 The Ohio State University Research Foundation Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
EP0156299A3 (en) * 1984-03-26 1987-04-01 Chiron Corporation Ltr modified viral vaccines
US4663436A (en) * 1984-04-24 1987-05-05 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4794168A (en) * 1984-04-24 1988-12-27 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4789702A (en) * 1984-05-18 1988-12-06 Cetus Corporation Feline leukemia virus vaccine
US4876089A (en) * 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4699785A (en) * 1984-09-18 1987-10-13 The Regents Of The University Of California Cell line producing feline leukemia virus
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
AU607427B2 (en) * 1986-05-30 1991-03-07 Cambridge Bioscience Corporation Method of preparation and use for feline leukemia virus antigens
GB2197321B (en) * 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
US5306493A (en) * 1986-10-03 1994-04-26 Miles Inc. FeLV-infected feline cell line
EP0262887A3 (en) * 1986-10-03 1989-07-26 Bayer Corporation Felv-infected feline cell line
JPH01501939A (ja) * 1987-01-28 1989-07-06 オーソ・フアーマシユーチカル・コーポレーシヨン 免疫抑制ペプチドおよび使用法
AU612404B2 (en) * 1987-09-11 1991-07-11 Genentech Inc. Method for increasing the expression of polypeptides in recombinant cell culture

Also Published As

Publication number Publication date
ES2179854T3 (es) 2003-02-01
AU4616289A (en) 1990-06-21
EP0699758B1 (en) 2002-07-24
DE68929419T2 (de) 2003-04-03
DK172633B1 (da) 1999-03-22
US6042835A (en) 2000-03-28
JP3164351B2 (ja) 2001-05-08
EP0699758A1 (en) 1996-03-06
DE68924478D1 (de) 1995-11-09
DE68924478T2 (de) 1996-03-07
DE68929419D1 (de) 2002-08-29
EP0377842A1 (en) 1990-07-18
IE960745L (en) 1990-06-13
AU661134B2 (en) 1995-07-13
JPH03117490A (ja) 1991-05-20
ATE128730T1 (de) 1995-10-15
NZ231744A (en) 1993-01-27
IE74875B1 (en) 1997-08-13
CA2005311C (en) 2006-05-30
EP0377842B1 (en) 1995-10-04
DK631089A (da) 1990-06-14
AU3710493A (en) 1993-07-15
CA2005311A1 (en) 1990-06-13
DK631089D0 (da) 1989-12-13
IE893974L (en) 1990-06-13
GR3018587T3 (en) 1996-04-30
ATE221119T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
EP1012295A4 (en) ALPHAVIRUS RNA REPLICON SYSTEMS
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
DE68929467D1 (de) HIV-2 Varianten
DK567387D0 (da) Fast rensemiddel, genanvendelig rengoeringspude indeholdende midlet og fremgangsmaade til fremstilling af midlet.
ES2034291T3 (es) Procedimiento para el tratamiento de emulsiones o de microemulsiones de aceite en agua contaminadas.
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
ES2187504T3 (es) Vectores no oncovirales, basados en el vmmp, con encapsidacion defectuosa.
EP0213894A3 (en) Defective viral particle vaccines and methods for their use
ES2179854T3 (es) Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas.
FI960375A0 (fi) Rakenneyksiköitä, joissa on nukleosidienvälisiä karbamaattisidoksia, ja niistä saatuja uusia oligonukleotideja
DE69523055D1 (de) T-zellen stimulierendes protein von pestivirus
DK76688A (da) Vaccine indeholdende f-proteinet fra aids-virus
NO973486D0 (no) Substituerte indanylidinacetylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikamenter eller diagnostikum og medikamenter inneholdende forbindelsene
BRPI0408643A (pt) mutante de vìrus clássico de doença bursal infecciosa, vacina para uso na proteção de aves domésticas, e, métodos para a preparação de um mutante de vìrus clássico de doença bursal infecciosa e para a preparação de uma vacina
ES2054841T3 (es) Vector viral y adn recombinante que codifica para una o unas proteinas de estructura (ha, f y/o np), de un morbilivirus.
BRPI0100837B8 (pt) sequência de dna que codifica a proteína externa de membrana antigênica e específica de salmonella typhi
FI890231A7 (fi) Çkaerlekssigillç, aer ett çlaosç som laoses antingen med verktyg eller foer hand, men som inte kan upplaoses utan att den gaor soender.
FI890387L (fi) Nya proteiner som haerletts ur maenniskans a2-plasmininhibitor eller liknande proteiner.
BR9909480A (pt) Método para gerar uma resposta à célula t citotóxica de um especìfico hiv em um hospedeiro
Buchwald Clean Your Room
London Studies of the observed and theoretical variations of atmospheric ozone(Final Report, 1 Jan. 1977- 30 Jun. 1990)
ES2084587T3 (es) Arn virus no revertientes.
FR2677666B1 (fr) Peptides ou polypeptides immunogenes du virus bvd et virus apparentes, vaccins les incorporant ou les exprimant, procedes et moyens de production y relatifs.
DE69021879D1 (de) Verfahren zur herstellung von impfstoffen gegen rna-virus.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 377842

Country of ref document: ES